Additional studies on the ability of cMD to predict cognitive decline and clinical progression in cohorts enriched for AD-risk factors such as APOE-ε4, autosomal dominant mutations, or other more stringent inclusion criteria, would be valuable to confirm our results. The gene discussed is APOE; the disease is Mental deterioration.